Langerhans cell histiocytosis (LCH) is a rare systemic disorder characterized by the accumulation of CD1a+/Langerin+ LCH cells and wide-ranging organ involvement.
Langerhans cell histiocytosis was formerly referred to as histiocytosis X, until it was renamed in 1987. Langerhans cell histiocytosis β was named for its morphological similarity to skin Langerhans cells. Studies have shown that LCH cells originate from myeloid dendritic cells rather than skin Langerhans cells. There has been significant debate regarding whether LCH should be defined as an immune disorder or a neoplasm. A breakthrough in understanding the pathogenesis of LCH occurred in 2010 when a gain-of-function mutation in BRAF (V600E) was identified in more than half of LCH patient samples. Studies have since reported that 100% of LCH cases show ERK phosphorylation, indicating that LCH is likely to be a clonally expanding myeloid neoplasm. Langerhans cell histiocytosis is now defined as an inflammatory myeloid neoplasm in the revised 2016 Histiocyte Society classification. Randomized trials and novel approaches have led to improved outcomes for pediatric patients, but no welldefined treatments for adult patients have been developed to date. Although LCH is not fatal in all cases, delayed diagnosis or treatment can result in serious impairment of organ function and decreased quality of life. This study summarizes recent advances in the pathophysiology and treatment of adult LCH, to raise awareness of this "orphan disease".
K E Y W O R D S
adult, histiocytosis, Langerhans cell, mitogen-activated protein kinase, proto-oncogene protein BRAF and aggressive disease that can lead to death. Any organ can be involved, individually or in combination, but bone and skin have a higher frequency of involvement. Diabetes insipidus (DI) is the most common initial sign of central nervous system (CNS) involvement in LCH. Isolated pulmonary LCH (PLCH), which is the most common manifestation in adult patients, is considered a specific type of LCH.
Although PLCH cells have similar histopathologic characteristics, the majority of cell proliferation is polyclonal. 8 Pulmonary LCH is strongly related to smoking; more than 90% of patients are smokers and quitting smoking could lead to remission without treatment. 
| ALTER ATI ON S OF THE MAPK PATHWAY IN LCH
The identification of an oncogenic BRAF -V600E mutation in more than half of all LCH cases represented a major advance in our understanding of the pathogenesis of LCH. 12 The BRAF protein is a member of the serine/threonine kinase RAF family, and is a key NVTAP486del, and 486_491NVTAPT>K), and a splicing mutation at the end of exon 12 (R506_K507insLLR) (Figure 1 ). [20] [21] [22] The kinase activity of these mutations has not been fully evaluated, but they might function similarly to BRAF-V600E, resulting in constitutive activation of BRAF. Additionally, BRAF-G466R, a missense mutation in the kinase domain of BRAF, has been described in LCH, although its function is also unknown. 23 In non-LCH histiocytosis, a BRAF-F595L mutation was identified in histiocytic sarcoma, 24 and an in-flame deletion-insertion (BRAF-T599_V600delinsRE) was identified in Erdheim-Chester disease (ECD 
| OTHER P OSS IB LE DRIVER S OF LCH
In addition to those noted above, a number of other mutations have been reported in LCH, although their role in its pathogenesis is unclear. One of the few possible drivers outside of MAPK is the PI3K (PI3K-AKT-mTOR) pathway. The PI3K pathway is an intracellular signaling pathway that regulates the cell cycle; activation of this pathway is a key driver of carcinogenesis. To date, three PI3K pathway alterations have been reported: PICK1, PIK3R2, and PIK3CA (Figure 2) . 33, 34 Of these, PIK3CA (E542K) is the only known activating somatic mutation, leading to constitutive activation of the PI3K pathway. Activating PIK3CA mutation is reported in 10%-20% of ECD cases, whereas only a single case was reported in LCH.
| THE CELL OF ORI G IN
As indicated by its name, LCH was believed to arise from skin and transforming growth factor-beta alone in vitro. 36 In contrast, which drives the development of histiocytosis in xenograft transplantation assays in vivo. 37 Constitutive activation of the MAPK pathway due to BRAF mutation plays a critical role in LCH. A previous study identified BRAF-V600E in CD34+ cells in patients with hairy cell leukemia. 38 Another study showed that BRAF-V600E expression in murine hematopoietic stem/progenitor cells can cause hairy cell leukemia-like disease. 39 It remains unclear why the same mutation occurring in hematopoietic cells leads to distinctly different conditions, suggesting that mechanisms other than BRAF might be involved.
| TRE ATMENT OP TI ON S FOR ADULT LCH
There are no standard therapies for adult LCH, and no prospec- 
| TRE ATMENTS FOR PRIMARY PLCH
As mentioned, primary PLCH in adults has a strong relation with smoking and nearly all the patients are smokers. Therefore, smoking cessation should be the top priority in the treatment of primary adult PLCH. In non-smokers or patients with progressive disease despite smoking cessation, systemic therapy of glucocorticoids or cladribine (2-CdA) could be an option. 10, 40, 41 It is important that radiation therapy is not useful in isolated PLCH. In patients with very aggressive PLCH with irreversible lung damage or severe pulmonary hypertension, lung transplantation might be considered. 42 
| TRE ATMENTS FOR SS-LCH
Local therapies are recommended for SS-LCH with isolated skin or bone involvement. Surgical excision of the lesion should be undertaken in very limited cases of SS-LCH with a solitary skin lesion. In skin-only cases, weekly oral methotrexate (MTX) with or without 6-mercaptopurine (or its prodrug azathioprine) is recommended. 43, 44 Light therapies in skinonly patients have been reported to be effective. 45, 46 In contrast to pediatric patients, radiotherapy could be an option for SS-LCH with bone lesions, with acceptable side-effects. [47] [48] [49] Recent reports have indicated that hydroxyurea with or without MTX or bisphosphonates might be effective in SS-LCH with multifocal bone lesions. [50] [51] [52] [53] However, in patients with multifocal bone involvement, systemic therapy equivalent to MS-LCH is often undertaken as initial treatment.
F I G U R E 3 Treatment algorithm for adult Langerhans cell histiocytosis (LCH). Diagnosis of LCH is based on histological and immunophenotypic examination. The primary indicators are characteristic LCH cells and positivity for CD1a and/or Langerin (CD207) cells.
Confirmation of cytoplasmic Birbeck granules by electron microscopy is no longer necessary. Complete patient history, including smoking history, must be determined, and specific physical examinations should be carried out, including neurological evaluation of central nervous system (CNS) and peripheral nerves. *In certain situations, such as involvement in vertebra or tissues near sensory organs, systemic therapy is recommended. **Involvement in craniofacial bones, eyes, ears, and oral cavity. MS, multisystem; PLCH, pulmonary LCH; SS, single system
| TRE ATMENTS FOR MS-LCH

Systemic therapy is strongly recommended for MS-LCH or SS-LCH
with multifocal bone lesions. No standard treatments have been identified but a combination of vinblastine and prednisolone therapy could serve as the standard option, as in pediatric LCH (Table 1) .
Adult patients who undergo vinblastine + prednisolone treatment tend to show higher toxicity than children, resulting in a poor overall response. [54] [55] [56] [57] Cytarabine or 2-CdA might be preferred as first-line treatments. 55, 58 For patients with CNS lesions, or primary or relapsed/refractory cases, 2-CdA and cytarabine are preferred because of their blood-brain barrier penetration. Retrospective analyses of short-course chemotherapy with MTX, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin in aggressive adult LCH have shown its efficacy. This intensive treatment should be reserved for very severe cases. 59 Allogeneic hematopoietic stem cell transplantation has been successful in some aggressive cases.
61,62
| TRE ATMENTS FOR HYP OTHAL AMIC-PITU ITARY MA SS LE S I ON
As mentioned, LCH can involve CNS and the most common manifestation is DI due to the hypothalamic-pituitary mass lesion. Mass lesions in hypothalamus and/or pituitary glands are often treated with vinblastine/prednisone or 2-CdA. 63, 64 Regardless of the treatment, most reported cases have shown that symptoms of DI or hormone dysfunction could not be reversed and requires constitutive hormone replacement therapy. safe. 70 A total of 11 adult ECD patients (including 4 overlapping with LCH) carrying BRAF-V600E were treated with a single dose of dabrafenib: 6 patients were pretreated with vemurafenib and treatment was discontinued due to toxicity; 1 experienced grade 3 toxicity (fever); and all achieved an at-least partial metabolic response. Papapanagiotou et al 71 reported successful treatment of MS-LCH with MEK1 (E102_I103delEI) mutation using trametinib, a MEK1/2 inhibitor. However, a cutaneous lesion reappeared after cessation of the treatment, which required retreatment.
| TARG E TED THER APIE S
| CON CLUS I ON AND PER S PEC TIVE S
Since the discovery of the BRAF-V600E mutation in LCH, advances 
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